Central Retinal Vein Occlusion

Overview of diagnosis and treatment of central retinal vein occlusion.

What is a Central Retinal Vein Occlusion?

The inner layers of the retina receive their blood supply from the central retinal artery. The blood returns to the heart through the central retinal vein. Both vessels enter the eye through a small opening in the middle of the optic nerve. Either because this opening shrinks or because the artery hardens or because of circulations problems, the central retinal vein can become partially or completely occluded. When a patient develops a central retinal vein occlusion (CRVO), they lose some or most of their central vision. The photograph of the retina on the right is of an eye with 20/50 visual acuity with a central retinal vein occlusion for 6 weeks. The retinal veins dilate and there are retinal hemorrhages. Patients often develop swelling of the central retina-cystoid macular edema--causing some of the vision loss. Without treatments, 25% of eyes improve, 50% stabilize, and 25% worsen.

Lucentis for Central Retinal Vein Occlusion

Monthly Lucentis therapy is also helpful in improving vision in patients with central retinal vein occlusion and macular edema. Without treatment about 15 percent of have visual improvement. With treatment about 50 percent of patients have improved vision. Long term follow-up show that at 4 years, a little over half of the patients with central retinal vein occlusion require continued treatment to maintain the visual benefit.


Eylea for Central Retinal Vein Occlusion

Monthly Eylea therapy is also helpful in improving vision in patients with central retinal vein occlusion and macular edema. Without treatment about 15 percent of have visual improvement. With treatment about 60 percent of patients have improved vision.


Central Retinal Vein Occlusion NEWS

Below are current articles from a Google News Feed on Central Retinal Vein Occlusion

Vitrectomy for macular edema due to retinal vein occlusion | OPTH  Dove Medical Press

Kazuyuki Kumagai,1 Nobuchika Ogino,2 Marie Fukami,1 Mariko Furukawa1 1Kami-iida Daiichi General Hospital, Aichi, Japan; 2Shinjo Ophthalmologic Institute, ...

The Value of Retinal Vein Occlusion Therapeutics Market Estimated to Soar Higher During 2015 – 2021  PortNews24

Retinal vein occlusion (RVO) is one of the major cause of visual loss among the geriatric population. RVO is the second common cause of blindness after ...

Central Retinal Vein Occlusion Global Clinical Trials Review, H2, 2018 Research Offer by The Market Reports  Industrial Journalism

This report provides top line data relating to the clinical trials on Central Retinal Vein Occlusion. Report includes an overview of trial numbers and their average ...

Bilateral central retinal vein occlusion as the first manifestation in chronic myeloid leukaemia  The BMJ

BMJ 2019; 364 doi: https://doi.org/10.1136/bmj.l685 (Published 21 February 2019) Cite this as: BMJ 2019;364:l685. Article; Related *content*; Metrics; Responses ...

Regeneron Pharmaceuticals, Inc. - Consenus Indicates Potential 27.5% Upside  DirectorsTalk Interviews

Regeneron Pharmaceuticals, Inc. found using ticker (REGN) have now 21 analysts covering the stock with the consensus suggesting a rating of 'Buy'. The.

Protective effects of ADM-RAMP2 system make it a new therapeutic target for retinal vein occlusion  Medical Xpress

A clot in the retinal vein can lead to severe and irreversible loss of vision. In a report in the American Journal of Pathology investigators utilize a newly developed ...

ADM-RAMP2 system could be therapeutic target for retinal vein occlusion  Drug Target Review

Researchers suggest that the retinoprotectivity of the ADM-RAMP2 system makes it an ideal therapeutic target for central retinal vein occlusion (CRVO).

A Novel Therapeutic Target for Retinal Vein Occlusion  Technology Networks

A clot in the retinal vein can lead to severe and irreversible loss of vision. In a report in the American Journal of Pathology investigators utilize a newly developed ...

Laser-induced chorioretinal anastomosis can lessen CRVO treatment burden  Healio

Adding laser-induced chorioretinal anastomosis to anti-VEGF treatment for central retinal vein occlusion can reduce the number of injections needed, according ...

Intravitreal Anti-Vascular Endothelial Growth Factor Injections for Macular Edema Associated With Central Retinal Vein Occlusion in Patients Age 40 Years or Younger  Healio

From Retina *Service*, Wills Eye Hospital, Mid Atlantic Retina, Thomas Jefferson University, Philadelphia, Pennsylvania (XG, AO, CMA, FSA, JFV, JH, ACH);and ...

Focus on Eyes: Vision loss and retinal vein occlusion  Florida Today

When a retinal vein is blocked, it can lead to severe loss of vision.

Retinal Vein Occlusion Therapeutics Market: Industry Analysis, Size, Share, Growth, Trends, And Forecasts 2019–2024  Burbank Observer

Retinal Vein Occlusion Therapeutics Market report on title “Global Retinal Vein Occlusion Therapeutics Market 2018 by Manufacturers, Countries, Type and ...

Retinal Vein Occlusion Market Rising Demand Seen in Healthcare at a CAGR of 11.2% by 2023 | By Types Branch Retinal Artery Occlusion, Central Retinal Vein Occlusion – Says MRFR |  Medgadget

Market Research Future published a research report on “Global Retinal Vein Occlusion Market” to track and analyses developments which are competitive in.

Avastin as effective as Eylea for treating central retinal vein occlusion  National Institutes of Health

Monthly eye injections of Avastin (bevacizumab) are as effective as the more expensive drug Eylea (aflibercept) for the treatment of central retinal vein occlusion ...

Global Retinal Vein Occlusion Therapeutics Market Professional Survey Report 2018  Honest Version

In this report, the Global Retinal Vein Occlusion Therapeutics market is valued at USD XX million in 2017 and is expected to reach USD XX million by the end of ...

Researchers confirm link between retinal vein occlusion, heart attack  Cardiovascular Business

In a large, retrospective study of the Taiwan population, researchers found individuals with retinal vein occlusion (RVO) demonstrated an adjusted risk increase ...

Easier treatment for blinding eye disease shows promise in clinical trial  Science Daily

A new study shows that an implantable delivery system for a widely used medication to treat a blinding eye disease has enabled some patients to go 15 months ...

Treatment arms for CRVO yield no difference in visual acuity results  Healio

BOSTON — Dexamethasone implant, ranibizumab injections or a combination of the two each yielded no statistically significant difference in visual acuity or ...

Central Retinal Vein Occlusion (CRVO)  News-Medical.net

Central retinal vein occlusion (CRVO) is the most common disease of the retinal vessels. It refers to a blockage of the vein draining the retinal tissue at the back ...

Ozurdex for retinal vein occlusion approved in China  Healio

The Chinese Food and Drug Administration has approved Ozurdex to treat adults with macular edema after branch retinal vein occlusion or central retinal vein ...

Anti-VEGF treatment of macular edema associated with retinal vein occl | OPTH  Dove Medical Press

Anti-VEGF treatment of macular edema associated with retinal vein occlusion: patterns of use and effectiveness in clinical practice (ECHO study report 2) J ...

Aflibercept Benefits Bevacizumab-Unresponsive Diabetic Retinopathy Patients  MD Magazine

A new analysis of an ongoing clinical study offers insights for treating retinal vein occlusion in poor responders to bevacizumab.

Fmr LLC Sells 924,371 Shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN)  Rockland Register

Fmr LLC decreased its position in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 17.3% in the 1st quarter, according to its most recent Form 13F filing ...

Biosimilars Reported Safe, Effective for Retinal Disease  Medscape

CHICAGO — Biosimilars made in India are as safe and effective for retinal vascular diseases as the American-made originator drugs, but cost about 40% less, ...

Retinal Vein Occlusion Therapeutics Market Size: Technological Advancement & Growth Analysis with Forecast to 2025 - Press Release  Digital Journal

The Retinal Vein Occlusion Therapeutics market report includes a comprehensive analysis of the competitive landscape of this vertical.- The report provides an ...

Complications After Intravitreal Injection Aggravate  Medscape

VANCOUVER, Canada — Clusters of inflammatory responses after intravitreal injections have unnerved some specialists, who will share their experiences and ...

Retinal Vein Occlusion Therapeutics Market 2019: Development Study by Global Industry Summary, Revenue, Gross Margin and Market Segment by 2024  The Port Bulletin

“Retinal Vein Occlusion Therapeutics Market Analysis, Development and Forecast 2019 – 2024” providing significant insights and providing a competitive ...

CRYSTAL study shows good results of personalized anti-VEGF treatment regimen in CRVO  Healio

Two-year results of the CRYSTAL study show that an as-needed medication regimen with frequent monitoring can reduce the number of anti-VEGF injections ...

FDA OKs Aflibercept (Eylea) for Diabetic Retinopathy  Medscape

The US Food and Drug Administration (FDA) has approved aflibercept (Eylea, Regeneron) injection solution to treat all stages of diabetic retinopathy, the ...

Eylea Market Share 2x more Than Lucentis in WMD and 3x more in DME/DR based on Medicare Claims Analysis  Dexur

Dexur's analysis of medicare claims shows that Eylea (Aflibercept) is being used twice as much as Lucentis (Ranibizumab) for Wet Age-related Macular ...

Cystoid Macular Edema Market Size Incredible Possibilities and Growth Analysis and Forecast To 2025  Digital Day News

Cystoid macular edema (CME) also known as Irvine Gass Syndrome is a painless disorder affecting the central retina or macula. This condition is characterized ...

SCORE2: Visual acuity results with bevacizumab non-inferior to aflibercept as treatment for macular edema due to CRVO  Healio

The SCORE2 study showed that intravitreal bevacizumab is non-inferior to aflibercept as a treatment for macular edema due to central retinal or hemiretinal vein ...

Bevacizumab as effective as aflibercept for central retinal vein occlusion  The Pharmaceutical Journal

Bevacizumab is frequently used off-label for treating macular oedema resulting from central retinal vein occlusion (CRVO), despite a lack of supporting data.

Retinal Vein Occlusion Associated With Stroke  Medscape

Retinal vein occlusion (RVO) is significantly associated with stroke development, according to a recent study. Although the investigators adjusted for potential ...

Surgical eye robot performs precision-injection in patient with retinal vein occlusion  Science Daily

Surgeons have operated on a patient with retinal vein occlusion using a surgical robot. Operated by an eye surgeon, the robot uses a needle of barely 0.03 ...

Regeneron Pharmaceuticals (NASDAQ:REGN) Downgraded to “Sell” at ValuEngine  Tech Know Bits

Regeneron Pharmaceuticals (NASDAQ:REGN) was downgraded by ValuEngine from a “hold” rating to a “sell” rating in a research report issued to clients and ...

Intravitreal corticosteroid implant vs intravitreal ranibizumab for th | DDDT  Dove Medical Press

Intravitreal corticosteroid implant vs intravitreal ranibizumab for the treatment of macular edema: a meta-analysis of randomized controlled trials Qingquan Wei,1 ...

Should We WAVE Goodbye to Laser?  Medscape

This study helps answer a common clinical question as to whether peripheral laser to areas of retinal ischemia improves vision and reduces injection burden in ...

RELATE study: Increased ranibizumab, laser yield minimal benefits  Healio

BOSTON — An increased dose of ranibizumab offered no added benefit in eyes with retinal vein occlusion, according to a study presented here. Additionally ...

IOP spikes more likely after treatment in certain patients  Healio

Mild to moderate IOP spikes were seen after multiple injections of Ozurdex for treatment of uveitis, diabetic macular edema and retinal vein occlusion, but ...

A Girl Whose Eyes Appear White in Photos  Medscape

A 6-year-old girl was referred to pediatric ophthalmology for a white reflex that was seen in photographs by her parents. Initially, the mother only saw the white ...

Retinal Vein Occlusion Market Report 2019 Top Companies, Sales, Revenue, Forecast and Detailed Analysis  Rochester Leader

This research by 360 Research Reports covers the current market size of the Retinal Vein Occlusion along with the growth rate over the years. In addition to this, ...

Cheap Avastin as effective as Eylea in CRVO  European Biotechnology

A study conducted by an NIH institute proves Roche's Avastin is as effective as Regeneron's Eylea, a drug that costs 30 times more than Roche's antibody.

Ozurdex® (dexamethasone 0.7mg) now available for millions of patients in China with macular edema secondary to retinal vein occlusion  Markets Insider

--An estimated 7.4 million people in China are living with this sight-threatening conditioni,ii,iii --. DUBLIN, March 22, 2018 /PRNewswire/ -- Today, Allergan plc ...

Three trials show efficacy of suprachoroidal CLS-TA injections for macular edema in uveitis  Healio

FORT LAUDERDALE, Fla. — Three clinical trials demonstrated rapid and sustained reduction of macular edema secondary to noninfectious uveitis in patients ...

FDA OKs Aflibercept (Eylea) for All Retinal Vein Occlusions  Medscape

The US Food and Drug Administration (FDA) has expanded the indication of aflibercept (Eylea, Regeneron) injection to include all forms of macular edema after ...

Case Report Highlights Acute Central Retinal Vein Occlusion in Scleroderma Patient  Scleroderma News

Researchers in Saudi Arabia at King Fahd Hospital of the University and the University of Dammam reported a case of a male patient with scleroderma who was ...

Roche-Genentech sees future for AI in retinal disease prevention  Healio

VANCOUVER, British Columbia — Roche-Genentech is working toward a future in which physician and machine come together to improve outcomes for ...

Retinal Vein Occlusion Market Clinical Research Analysis 2019 to 2025  Market Research Periodical

The report presents an in-depth assessment of the Retinal Vein Occlusion including enabling technologies, key trends, market drivers, challenges, ...

Anti-VEGF Therapy Before Steroids for Retinal Vein Occlusion  Medscape

NICE, France — Aflibercept and ranibizumab are safer than dexamethasone intravitreal implants for the treatment of central retinal vein occlusion, a new study ...

High systolic BP affects your retina and may lead to complete vision loss  Economic Times

Constant fluctuations in the systolic pressure can lead to many major eye complications.

Blue Light Damages Retinal Cells in Lab Study  Medscape

A cell-based experiment shows how blue light can damage retinal cells, but it's unclear whether the results translate to humans or if blue light exposure from ...

Topical Squalamine 0.2% and Intravitreal Ranibizumab 0.5 mg as Combination Therapy for Macular Edema Due to Branch and Central Retinal Vein Occlusion: An Open-Label, Randomized Study  Healio

Ophthalmic Surgery, Lasers and Imaging Retina | BACKGROUND AND OBJECTIVE:To evaluate the effects of squalamine (OHR-102; Ohr Pharmaceuticals, ...

Retinal artery and vein thrombotic occlusion during pregnancy: markers | OPTH  Dove Medical Press

Retinal artery and vein thrombotic occlusion during pregnancy: markers for familial thrombophilia and adverse pregnancy outcomes Will S Kurtz,1 Charles J ...

Europe's Luxturna approval tops November retina news  Healio

The European Commission's approval of Luxturna for inherited retinal disease was the most-read retina-related article on Healio.com/OSN in November.

Topical timolol-dorzolamide combined with anti-VEGF could better treat macular edema  Healio

PHILADELPHIA – An ongoing study suggests that topical timolol-dorzolamide can reduce central subfield thickness in patients with persistent macular edema ...

Regeneron Pharmaceuticals (NASDAQ:REGN) Upgraded to “Hold” at ValuEngine  Rockland Register

Regeneron Pharmaceuticals (NASDAQ:REGN) was upgraded by research analysts at ValuEngine from a “sell” rating to a “hold” rating in a report released on ...

Biosimilar Ranibizumab Effective in Treating RVO in a Real-World Setting  The Center for Biosimilars

In India, Razumab, manufactured by Intas Pharmaceuticals, was approved as a similar biologic to ranibizumab in 2015; the retrospective study RE-ENACT ...

Essay: Mom sees life from the sunny side  Newsday

Five days before Christmas 2016, my vivacious, bubbly, loving mother, Vivian Schachter, suddenly lost most of her vision. She had central retinal vein occlusion.

Biosimilars for bevacizumab and ranibizumab show promise for retinal diseases  Healio

VANCOUVER, British Columbia — Data for two new biosimilars for ranibizumab and bevacizumab, currently available in India, show the treatments are safe and ...

Monthly, PRN doses of ranibizumab similarly effective in RVO  Healio

TORONTO — As-needed and monthly ranibizumab dosing regimens yielded similar visual acuity gains in patients with retinal vein occlusion who reached a ...

New gene therapy for vision loss proven safe in humans  Medical Xpress

In a small and preliminary clinical trial, Johns Hopkins researchers and their collaborators have shown that an experimental gene therapy that uses viruses to ...

CRAO and Stroke Risk: Is Neurological Evaluation Warranted?  Medscape

Patients with central retinal artery occlusion may be at an increased risk for stroke and may benefit from prompt neurological evaluation, according to a new ...

Regeneron (REGN) to Report Q1 Earnings: What's in Store?  Yahoo Finance

Regeneron Pharmaceuticals, Inc. REGN is scheduled to release first-quarter 2019 results on May 7, before the opening bell. In the last reported quarter, the ...

BLOG: Laser still has an important role in diabetic eye disease  Healio

Ophthalmology Blogs | Mali | There is no question that the introduction of anti-VEGF agents has dramatically changed the landscape of how surgeons approach ...

Disorganization of Retinal Inner Layers Linked to Visual Acuity Prognoses  MD Magazine

A new study suggests patients with disorganized retinal inner layers see lesser levels of visual acuity improvement after therapy.

Genentech Unveils Positive Phase II Results for the First-Ever Eye Implant to Achieve Sustained Delivery of a Biologic Medicine to Treat People With Wet Age-Related Macular Degeneration (AMD)  BioSpace

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced positive, top line results from the Phase II LADDER study ...

Array BioPharma Announces BRAFTOVI + MEKTOVI + Cetuximab Meet Primary Endpoints of ORR and OS in Phase 3 BEACON CRC Trial Interim Analysis for the Treatment of BRAF(V600E)-mutant Metastatic Colorectal Cancer  PRNewswire

BOULDER, Colo., May 21, 2019 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) today announced positive results from the interim analysis of the Phase ...

Global Retinal Vein Occlusion Therapeutics Market 2019 Professional Survey Report Forecast To 2024  The Norman Gazette

Global Retinal Vein Occlusion Therapeutics Market gives valuable reviews and key research including the conventional market patterns, forthcoming and ...

High Blood Pressure, High Cholesterol May Be Associated With Retinal Vascular Disease  Science Daily (press release)

High blood pressure and high cholesterol levels appear to be risk factors for retinal vein occlusion, a condition that causes vision loss, according to a new article.

AAP Updates Screening Policy for ROP  Medscape

Premature infants require regular screening for retinopathy of prematurity (ROP), according to an updated policy statement from the American Academy of ...

Regeneron Pharmaceuticals (REGN) Receives Hold Rating from Canaccord Genuity  Rockland Register

Regeneron Pharmaceuticals (NASDAQ:REGN)'s stock had its “hold” rating reiterated by research analysts at Canaccord Genuity in a report issued on ...

NICE backs Bayer's Eylea as first-line BRVO treatment  PMLiVE

Bayer's Eylea (aflibercept) has been recommended for use on the NHS in England and Wales as a first-line treatment for adults with branch retinal vein ...

AI System Accurately Detects 53 Kinds of Eye Disease  Medscape

Artificial intelligence (AI) is at least as effective as experts, and sometimes more effective, in detecting 53 kinds of sight-threatening retinal diseases, according to ...

EC OKs Gene Therapy Luxturna for Inherited Retinal Dystrophy  Medscape

The European Commission (EC) has approved voretigene neparvovec (Luxturna, Spark Therapeutics) for children and adults with vision loss due to inherited ...

Reviewing Coherus BioSciences Inc. (CHRS)'s and Principia Biopharma Inc. (NASDAQ:PRNB)'s results  Stocks Beat

Both Coherus BioSciences Inc. (NASDAQ:CHRS) and Principia Biopharma Inc. (NASDAQ:PRNB) compete on a level playing field in the Biotechnology industry.

UBS Group Trims Regeneron Pharmaceuticals (REGN) Target Price to $440.00  Rockland Register

Regeneron Pharmaceuticals (NASDAQ:REGN) had its target price trimmed by UBS Group from $480.00 to $440.00 in a research note published on Wednesday ...

New AI Approach to Optical Coherence Tomography Images  Medscape

CHICAGO — Artificial intelligence programs can be trained to read optical coherence tomography (OCT) images in the same way that humans learn, by looking ...

TANZANITE study: No re-treatments required with triamcinolone acetonide formulation after 3 months  Healio

A majority of patients treated with a proprietary form of triamcinolone acetonide in combination with aflibercept required no additional treatments over 3 months ...

Allergan Receives Approval for Ozurdex® (Dexamethasone Intravitreal Implant 0.7 mg) in China for the Treatment of Retinal Vein Occlusion (RVO)  PR Newswire

DUBLIN, Oct. 30, 2017 /PRNewswire/ -- Allergan plc (NYSE: AGN) announced today that it has received an Imported Drugs License (IDL) from the Chinese Food ...

RETINA-AI Releases Android Version of Fluid-Intelligence -- World's First Mobile Artificial Intelligence App for Eye Care Providers  AiThority

RETINA-AI has released an Android version of its app Fluid-Intelligence, the world's first mobile artificial intelligence (AI) app for eye care providers. The app can ...

Eye Testing May Aid Early Diagnosis of Creutzfeldt-Jakob Disease  Medscape

Eye examinations may aid clinicians in the diagnosis of sporadic Creutzfeldt-Jacob disease (sCJD), results of a small postmortem study show. In an evaluation ...

Switching to Aflibercept Demonstrates Improvement in VA, CST for Poor Responders to Bevacizumab in SCORE2  MD Magazine

Those who were switched to aflibercept improved 9 letters of VA, and 110 µm in CST from months 6 to 12.

New Geographic Atrophy Treatment Shows Promise  Medscape

VANCOUVER, Canada — An experimental treatment with an intravitreal complement C3 inhibitor (APL-2, Apellis Pharmaceuticals) slowed geographic atrophy ...

Effect of intravitreal aflibercept on corneal endothelial cells: a 6-m | OPTH  Dove Medical Press

Tetsuya Muto, Shigeki Machida Department of Ophthalmology, Dokkyo Medical University Saitama Medical Center, Koshigaya, Japan Purpose: To determine ...

Central retinal vein occlusion (CRVO): Types, causes, symptoms, and treatment  Bel Marra Health

Central retinal vein occlusion (CRVO) refers to a medical condition of the eye where the main vein of the retina has become blocked. Much like other organs of ...

Regeneron Pharmaceuticals (NASDAQ:REGN) Rating Lowered to Sell at ValuEngine  Rockland Register

Regeneron Pharmaceuticals (NASDAQ:REGN) was downgraded by equities researchers at ValuEngine from a “hold” rating to a “sell” rating in a research report ...

Regeneron Pharmaceuticals Inc (REGN) Position Cut by CIBC Asset Management Inc  Mayfield Recorder

CIBC Asset Management Inc lessened its position in shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 0.6% in the first quarter, according to the ...

Regeneron Pharmaceuticals (REGN) Given Hold Rating at Cowen  Rockland Register

Regeneron Pharmaceuticals (NASDAQ:REGN)'s stock had its “hold” rating reaffirmed by Cowen in a research report issued on Tuesday, May 7th, ...

Bayer files eye drug Eylea for new use in EU  PMLiVE

Bayer has filed an application to extend the indications of its ophthalmic drug Eylea in Europe to include use in patients with branch retinal vein occlusion ...

EU Panel Recommends Luxturna for Inherited Retinal Dystrophy  Medscape

The EMA's CHMP has recommended marketing authorization for voretigene neparvovec for inherited retinal dystrophy caused by RPE65 gene mutations in ...

BidaskClub Lowers Regeneron Pharmaceuticals (REGN) to Strong Sell  Rockland Register

Regeneron Pharmaceuticals (NASDAQ:REGN) was downgraded by equities researchers at BidaskClub from a “sell” rating to a “strong sell” rating in a research ...

Increase in choroidal thickness seen after CPAP therapy  Healio

Patients with obstructive sleep apnea syndrome who underwent continuous positive airway pressure therapy experienced an increase in choroidal thickness ...

Aflibercept Injections Superior to Laser for Macular Edema  Medscape

Intravitreal injections of aflibercept were more effective than laser therapy for the treatment of macular edema secondary to branch retinal vein occlusion, ...

Regeneron's 12-Week Eylea Dose Gets CRL From FDA for Wet AMD  Nasdaq

Regeneron Pharmaceuticals, Inc . REGN suffered a setback when the FDA issued a complete response letter (CRL) to its supplemental Biologics License.

Revealing the retina: Graphene corneal contact lens provides robust, irritation-free topographic electroretinography  Phys.org

Our vision can be damaged or lost by damage to the retina—a sensory membrane lining the back of the eye that senses light, converting the image formed into ...

Bevacizumab, Ranibizumab Biosimilars Proven Effective, Safe for Retina Diseases  MD Magazine

The cheaper intravitreal anti-VEGF options improved visual acuity in the eyes of patients with 5 different retinal conditions.

Steroid Injections May Help Restore Vision In Some Patients With Blocked Eye Veins  Science Daily (press release)

Injecting the eye with the corticosteroid triamcinolone appears effective in improving the vision of some patients with retinal vein occlusion, an important cause of ...

The Algorithm Will See You Now: Artificial Intelligence May Transform Retinal Screening  Medscape

The pursuit of artificial intelligence (AI)—machine simulation of human cognitive behavior—began in earnest in the 1950s. Advances in the 21st century, ...

VEGF Inhibition Improves Visual Acuity in Macular Edema  Medscape

Ranibizumab improved visual acuity at 6 months in patients with macular edema secondary to ischemic branch retinal vein occlusion, whether or not they ...

» Load more